Wei Liu

Dr. Wei Liu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in European Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
HZHuiqiong Zeng
Huiqiong Zeng
JLJunda Lai
Junda Lai
ZLZhihang Liu
Zhihang Liu
WLWei Liu
Wei Liu
YZYe Zhang
Ye Zhang
Objective Gout, common metabolic disorders, have poorly understood links with blood metabolites. Exploring these relationships could enhance clinical prevention and treatment strategies. Methods We applied bidirectional two-sample Mendelian randomization (MR) analysis, using data from a genome-wide association (GWAS) study of 486 blood metabolites. Gout data was obtained from FinnGen R8 (7461 gout and 221,323 control cases). We implemented the inverse variance-weighted (IVW) method for main analytical approach. Extensive heterogeneity, pleiotropy tests, leave-one-out analysis, and reverse MR were conducted to validate the robustness of our findings. Both Bonferroni and False Discovery Rate (FDR) corrections were used to adjust for multiple comparisons, ensuring stringent validation of our results. Results Initial MR identified 31 candidate metabolites with potential genetic associations to gout. Following rigorous sensitivity analysis, 23 metabolites as potential statistical significance after final confirmation. These included metabolites enhancing gout risk such as X-11529 (OR = 1.225, 95% CI 1.112–1.350, P < 0.001), as well as others like piperine and stachydrine, which appeared to confer protective effects. The analysis was strengthened by reverse MR analysis. Additionally, an enrichment analysis was conducted, suggesting that 1-methylxanthine may be involved in the metabolic process of gout through the caffeine metabolism pathway. Conclusion Identifying causal metabolites offers new insights into the mechanisms influencing gout, suggesting pathways for future research and potential therapeutic targets.

16 June 2026 in ACS Omega
Verified
Journal Article
Open access
HZHuiqiong Zeng
Huiqiong Zeng
SLSongqing Lin
Songqing Lin
ZLZebin Liu
Zebin Liu
JLJunda Lai
Junda Lai
WLWei Liu
Wei Liu
YZYe Zhang
Ye Zhang
Background: Gout, an inflammatory arthritis driven by urate crystal deposition, still lacks therapies that are effective and well-tolerated. T-614 (iguratimod), an immunomodulatory drug approved for rheumatoid arthritis, has shown promise in Gout, but its molecular and immunogenetic mechanisms remain unclear. Methods: We assessed the druggability and pharmacokinetic properties of T-614 using SwissADME and ADMET Lab 2.0. Network pharmacology identified overlapping targets between T-614 and Gout and constructed a STRING-based protein–protein interaction network with GO/KEGG enrichment. A two-sample Mendelian randomization (MR) analysis of 731 immune-cell traits and Gout (FinnGen R9) identified causal immunophenotypes. Molecular docking, 100 ns molecular dynamics (MD) simulations, and MM/GBSA calculations were carried out for AKT1 (with docking support for TNF and IL1B). Public single-cell RNA sequencing (scRNA-seq) data of peripheral blood mononuclear cells were analyzed to profile cell-type-specific expression of core targets. Results: T-614 displayed favorable oral drug-likeness (QED = 0.641), high predicted plasma protein binding (PPB ≈ 94.22%), and limited blood–brain barrier penetration. AKT1, TNF, and IL1B were prioritized as putative hub targets by network-based analyses in PI3K/AKT, MAPK, and TNF signaling. Docking and representative MD/MM-GBSA analyses supported a thermodynamically favorable and dynamically stable binding mode AKT1/T-614 complex. MR identified 29 immune-cell traits genetically associated with Gout susceptibility, providing population-level causal inference and highlighting proinflammatory CD16+ monocytes and dysfunctional CD25+ Tregs, and scRNA-seq confirmed expression of AKT1, TNF, and IL1B in these Gout-relevant immune subsets. Conclusion: This integrative in silico framework suggests that T-614 could structurally engage multiple immunomodulator targets relevant to Gout and generates genetically and cell-type-informed hypotheses that require biochemical, cellular, and in vivo validation.